ARVINAS INC
NASDAQ: ARVN (Arvinas, Inc.)
Kemas kini terakhir: 2 hari lalu, 12:09AM7.72
0.49 (6.78%)
| Penutupan Terdahulu | 7.23 |
| Buka | 7.32 |
| Jumlah Dagangan | 8,592,486 |
| Purata Dagangan (3B) | 2,748,911 |
| Modal Pasaran | 563,493,568 |
| Harga / Jualan (P/S) | 1.30 |
| Harga / Buku (P/B) | 0.850 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Jul 2025 - 1 Aug 2025 |
| Margin Keuntungan | -10.92% |
| Margin Operasi (TTM) | 37.82% |
| EPS Cair (TTM) | -0.660 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 646.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.59% |
| Nisbah Semasa (MRQ) | 4.58 |
| Aliran Tunai Operasi (OCF TTM) | -259.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -99.28 M |
| Pulangan Atas Aset (ROA TTM) | -5.39% |
| Pulangan Atas Ekuiti (ROE TTM) | -7.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Arvinas, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.88 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 7.18% |
| % Dimiliki oleh Institusi | 104.84% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 51.00 (Stifel, 560.62%) | Beli |
| Median | 20.00 (159.07%) | |
| Rendah | 10.00 (Jefferies, 29.53%) | Pegang |
| Purata | 22.80 (195.34%) | |
| Jumlah | 10 Beli, 5 Pegang | |
| Harga Purata @ Panggilan | 10.24 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 02 May 2025 | 16.00 (107.25%) | Beli | 7.72 |
| HC Wainwright & Co. | 02 May 2025 | 24.00 (210.88%) | Beli | 7.72 |
| 07 Apr 2025 | 81.00 (949.22%) | Beli | 6.37 | |
| Jefferies | 02 May 2025 | 10.00 (29.53%) | Pegang | 7.72 |
| Piper Sandler | 02 May 2025 | 14.00 (81.35%) | Beli | 7.72 |
| Goldman Sachs | 17 Apr 2025 | 12.00 (55.44%) | Pegang | 8.60 |
| Truist Securities | 09 Apr 2025 | 21.00 (172.02%) | Beli | 6.73 |
| Guggenheim | 13 Mar 2025 | 32.00 (314.51%) | Beli | 8.55 |
| 12 Feb 2025 | 57.00 (638.34%) | Beli | 17.95 | |
| Morgan Stanley | 13 Mar 2025 | 12.00 (55.44%) | Pegang | 8.55 |
| B of A Securities | 12 Mar 2025 | 28.00 (262.69%) | Beli | 9.03 |
| BMO Capital | 12 Mar 2025 | 20.00 (159.07%) | Beli | 9.03 |
| 12 Feb 2025 | 82.00 (962.18%) | Beli | 17.95 | |
| Wedbush | 12 Mar 2025 | 12.00 (55.44%) | Pegang | 9.03 |
| Wells Fargo | 12 Mar 2025 | 26.00 (236.79%) | Beli | 9.03 |
| Citigroup | 07 Mar 2025 | 19.00 (146.11%) | Pegang | 18.28 |
| Oppenheimer | 12 Feb 2025 | 45.00 (482.90%) | Beli | 17.95 |
| Stifel | 12 Feb 2025 | 51.00 (560.62%) | Beli | 17.95 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |